Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 3Solid Tumors 2Melanoma 2Carcinoma 2Adult Solid Neoplasm 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Neoplasm 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteolysis 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Malignant Solid Tumour 1Liver Neoplasms 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1

Interventions

Zoledronic Acid 5Risedronic Acid 4Vitamin D 3Denosumab 3Letrozole 2Calcium 2Toremifene 1Radiography, Panoramic 1Nutrition Assessment 1Kyphoplasty 1Ibandronic Acid 1Health Promotion 1Geritol 1Exercise 1Calcium Carbonate 1Aromatase Inhibitors 1Anastrozole 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bone Diseases, Metabolic × ARQ 197 × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡